Generic Name and Formulations:
Pyrazinamide 500mg; scored tabs.
Various generic manufacturers
Indications for Pyrazinamide:
Susceptible pulmonary tuberculosis.
Adults and Children:
15–30mg/kg once daily; max 2g daily. Or 50–70mg/kg twice weekly based on lean body weight.
Severe hepatic damage. Acute gout.
Use with other antituberculars. Monitor hepatic function and serum uric acid before and during therapy. Hepatocellular damage or hyperuricemia with acute gouty arthritis: discontinue. Patients at risk for hepatitis (eg, alcoholism). Diabetes (blood glucose may be harder to control). HIV: see literature. Pregnancy (Cat.C). Nursing mothers.
May interfere with Acetest or Ketostix.
Hepatitis, liver dysfunction, gout, GI disturbances, arthralgia, myalgia, blood dyscrasias (rare).
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC